For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250428:nRSb4887Ga&default-theme=true
RNS Number : 4887G Walker Crips Group plc 28 April 2025
28 April 2025
Walker Crips Group plc
("Walker Crips" or the "Company")
Appointment of Non-Executive Director
Walker Crips Group plc announces that Mark Nelligan has joined the Company as
Independent Non-Executive Director, and Chair of the Company's audit
committee, effective from 25 April 2025.
Mark is a Chartered Accountant and began his career at Arthur Andersen &
Co, then took on management roles at Glaxo Holdings plc and ING Barings, where
he was based in India, Hong Kong, and then Singapore. He then joined Pershing
Securities Singapore, a Bank of New York Mellon company in 2002 until 2023,
where he was Executive Chair & CEO before relocating back to London.
Jo Welman, incoming Chairman, commented: "Mark has extensive senior executive
and non-executive experience in financial services and has grown businesses in
highly regulated environments and has interacted with regulators across many
jurisdictions. His international experience and previous senior leadership
role within Pershing Securities will be immensely beneficial to the firm. We
look forward to working with Mark and the wealth of experience he brings to
our business."
Walker Crips Group plc confirms that there are no details that require
disclosure under UK Listing Rule 6.4.8R in respect of Mark Nelligan.
For further information, please contact:
Walker Crips Group plc Tel: +44 (0)20 3100 8000
Craig Harrison, Media Relations
Singer Capital Markets Tel: +44 (0)20 7496 3000
Charles Leigh-Pemberton / Asha Chotai
Further information on Walker Crips Group is available on the Company's
website: www.walkercrips.co.uk (http://www.walkercrips.co.uk/)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END BOAZVLFLEZLZBBF